A Phase 3 Multicenter Randomized Double-blind Placebo-controlled Trial to Evaluate the Efficacy Safety and Tolerability of Brexpiprazole as Adjunctive Therapy in the Maintenance Treatment of Adults With Major Depressive Disorder

Trial Image

Study Overview

This trial is a phase 3, double-blind, placebo-controlled, randomized withdrawal maintenance trial of brexpiprazole in subjects who require adjunctive treatment of MDD designed to fulfill a post-marketing commitment to the US Food and Drug Administration (FDA). There is a paucity of data on long-term use of the combination of ADT and an antipsychotic drug.The trial will assess long-term benefit of continuation of adjunctive therapy in subjects who achieve a level of clinical stabilization.

  • Study Identifier: 831294

Recruitment Status

Open

Contact the research team to learn more about this study.

Fields marked with asterisk (*) are required

Please verify that you are not a bot.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Volunteer Sign up

Volunteer Sign-up

Participate in medical studies to develop new diagnostic and clinical treatments and improve current standards of care.

Sign Up Now!

If you need assistance finding a non-cancer study or if you have any questions, please email psom-ocr@pobox.upenn.edu